LearnGlossaryMarketStocksSuperinvestorsSign in

PTCT

PTC Therapeutics, Inc.

Healthcare · $5.4B market cap

Verdict

We can't put a fair value on PTCT right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-5.4% a year✗
Sales growth29.9% a year✓
Free cash flow growth—?
Return on invested capital-3.5%✗

Follow PTCT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds PTCT. In Q2 2026, 1 opened a position. Who we track

Polen Capital Management

Polen Capital Management · as of Q2 2026

$2.0M

24,916 shares

Moves in Q2 2026

New position: Polen Capital Management

Insider activity

Since Sep 9, 2026: no open-market purchases and 3 sales worth $1.4M. Why purchases matter

Sales

SCHMERTZLER MICHAEL

director · 2026-09-10

Sold

$673K

SCHMERTZLER MICHAEL

director · 2026-09-09

Sold

$39K

SCHMERTZLER MICHAEL

director · 2026-09-09

Sold

$639K

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works